WHO vaccine-preventable diseases: monitoring system. 2014 global summary

Last updated 05-Dec-2014 (Data received as of 1-Dec-2014)
Next overall update June 2015
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 34'1201 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 32'7601 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2013  2012  2011  2010  2009  2000  1990  1980 
Total population 7'733  7'644  7'542  7'420  7'274  6'014  4'499  3'745 
Births 157  156  155  154  152  127  100  93 
Surviving infants 156  156  155  153  151  127  99  92 
Pop. less than 5 years 782  772  758  735  722  614  483  458 
Pop. less than 15 years 2'145  2'109  2'069  2'021  1'991  1'689  1'406  1'237 
Female 15-49 years 1'817  1'803  1'785  1'764  1'735  1'503  1'096  874 

Number of reported case

(Click for retrospective incidence data for Israel)
Diphtheria
Japanese encephalitis
Measles 50  211  70  23  36  230  215 
Mumps 51  93  301  4'923  775  48 
Pertussis 1'394  2'730  2'345  1'244  1'182  452  155  19 
Polio* 11 
Rubella 54 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Israel)
Vaccine year result method % card seen                                                
BCG          75 
DTP1          96  97  94 
DTP3          94  95  96  96  93  84 
HepB_BD          100 
HepB3          98  97  99  97 
Hib3          94  95  96  94 
JapEnc         
MCV          97  96  98  97  91  81 
MCV2          95  95  93  92  92 
PCV1         
PCV3          92  92 
Pol3          94  95  94  92  93  85 
Rota1         
Rota_last         
Rubella1          97  96  98  97 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2015

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Israel)
BCG 75 
DTP1 95  95  95  95  98  98  97  94 
DTP3 94  94  94  95  96  96  93  84 
HepB3 98  98  98  97  99  97 
HepB_BD 99  99  99  99  99  99 
Hib3 94  94  94  95  96  94 
MCV 97  97  97  96  98  97  91  81 
MCV2 95  95  93  92  92 
PnC3 92  92  92 
Pol3 94  94  94  95  94  92  93  85 
Rota_last

Number of districts in the country 15  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 93
From 80 to 89% 7
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2013 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG Yes risk groups
DT 2, 4, 6, 12 months; Yes if Pertussis contraindicated
DTaP 2, 4, 6, 12 months; Yes
DTaPHibIPV 2, 4, 6, 12 months; Yes
HPV 13 years; + 2, +6 months; Yes or women from 9 to 45 years old
HepA 18, 24 months; Yes and risk groups
HepB birth; 1, 6 months; Yes and risk groups & travellers
Hib 2, 4, 6, 12 months; Yes risk groups
IPV Yes risk groups, catch up
Influenza > 6 months; Yes general population
JapEnc 0, 7, 28 days; Yes Travellers:0 and 28 days
MMR 12 months; 6 years; Yes and risk groups
MMRV 12 months; 6 years; Yes
MenACWY Yes risk groups
OPV 6, 18 months; Yes From January 2014
Pneumo_conj 2, 4, 12 months; Yes
Pneumo_ps >= 65 years; Yes risk groups
Rotavirus 2, 4, 6 months; Yes
TBE Yes Travellers
Td Yes every ten years to adult population and for tetanus prophilaxis in wound management
TdaPIPV 7 years; Yes
Tdap 14 years; Yes
Typhoid Yes Travellers
TyphoidHepA Yes Travellers
Varicella 12 months; 6 years; Yes and risk groups
YF Yes Travellers

Immunizaton indicators

Indicator Expected answer 2013  2012  2011  2010  2009  2008  2007 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number     10 years  5 years  5 year  5 years 
Nº of districts with microplans that include activities to raise immunization coverage number 15  15  15  15  15  15  15 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes       

System performance

Total Nº districts in country number 15  15  15  15  15  15  15 
Nº districts with DTP3 coverage >=80% number 15  15  15  15  15  15 
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100  100  100  100 
Nº districts with measles (MCV1) coverage >=95% number 15  15       
% of districts with MCV1 coverage >=95% From 0 to 100% 100  100       

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes       
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Estimated percentage of routine vaccines funded by Government From 0 to 100%           N.D.   

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.